Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05189769 · ClinicalTrials.gov registry record · NA
Reducing Racism and Discrimination in Schools: Comprehensive Prevention Services
A NA study of Behavior, Child, sponsored by University of Alabama, Tuscaloo.
- Active
- Registry status
- NA
- Development phase
- 1,093
- Enrollment target
- 2
- Study locations
NCT05189769: Active NA study of Behavior, Child, sponsored by University of Alabama, Tuscaloo.
NCT05189769 is a NA study of Behavior, Child that is active but no longer recruiting, run by University of Alabama, Tuscaloo. The registered enrollment target is 1,093 participants, above the 731-participant average among 5 other Behavior, Child trials with a reported enrollment target (50% higher). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05189769, a NA study of Behavior, Child, is active but no longer recruiting, sponsored by University of Alabama, Tuscaloo.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 1,093 participants
- Enrollment target
- 2
- Study locations
Study Summary
The primary purpose of this project is to test a comprehensive, two-part intervention with ReACT and a recently adapted, Coping Power+ Program. ReACT and PBIS are school-wide universal interventions. Coping Power and Coping Power+ are targeted preventive interventions designed to assist at-risk 7th grade students to improve their coping with interpersonal stressors during middle school. This project will evaluate the effects of the program on teacher, student and parent perceptions of school climate, student behavior, social-emotional competence, disciplinary infractions, and identity for 7th grade students in Coping Power or Coping Power+
Primary Outcome
his 6-item screener will be completed on all students in participating classrooms. Higher scores indicate more risk to determine the top 25% of the scoring students who will be considered participants in the CP and CP+ groups. T
Conditions Studied
Interventions
- BEHAVIORAL CP no REACT
- BEHAVIORAL CP+/No REACT
- BEHAVIORAL CP and REACT
- BEHAVIORAL CP+ and REACT
Study Locations (2)
Alabama
- Jefferson County Public Schools - Birmingham
- Huntsville City Schools - Huntsville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,093 participants |
| Start Date | 2019-05-15 |
| Est. Completion | 2025-12-01 |
| Phase | NA |
What the registry record for NCT05189769 still lists
NCT05189769 is an interventional study that assigns participants to a tested intervention. Its 1,093 participants enrollment target places it among the larger protocols in the corpus, above the 731-participant average among 5 other Behavior, Child trials with a reported enrollment target (50% higher).
The record links to 1 condition, with Behavior, Child appearing as the primary indexed condition, and to 4 interventions - of which CP no REACT is the first listed.
NCT05189769 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT05189769 about?
NCT05189769 is a clinical study titled "Reducing Racism and Discrimination in Schools: Comprehensive Prevention Services". The primary purpose of this project is to test a comprehensive, two-part intervention with ReACT and a recently adapted, Coping Power+ Program. ReACT and PBIS are school-wide universal interventions. Coping Power and Coping Power+ are targeted preventive interventions designed to assist at-risk 7th ...
What is the current status of trial NCT05189769?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 1,093 participants. The study started on 2019-05-15. Estimated completion is 2025-12-01.
What conditions does trial NCT05189769 study?
This clinical trial studies the following conditions: Behavior, Child.
What interventions are being tested in trial NCT05189769?
The interventions under investigation include: CP no REACT (BEHAVIORAL), CP+/No REACT (BEHAVIORAL), CP and REACT (BEHAVIORAL), CP+ and REACT (BEHAVIORAL).
Who is sponsoring clinical trial NCT05189769?
This trial is sponsored by University of Alabama, Tuscaloo, which has 17 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05189769 being conducted?
This trial has 2 study locations across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Behavior, Child
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
PRT for Adolescents With High Functioning Autism
RECRUITING · NA
-
BASIS-T Efficacy Trial
RECRUITING · NA
-
Randomized Controlled Trial of a Behavioral Training App
RECRUITING · NA
-
Impact of Pre-Sedation Virtual Reality Game on Post-Discharge Negative Behaviors in the Pediatric Emergency Department
COMPLETED · NA
-
Nudging for Behavior Change in School Cafeterias
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03754114 · 1,094 participants · NA
Brain Oxygen Optimization in Severe TBI, Phase 3
- NCT06118983 · 1,094 participants · NA
Improving TRansitions ANd OutcomeS for Heart FailurE Patients in Home Health CaRe (I-TRANSFER-HF)
- NCT06585241 · 1,094 participants · Phase 4
A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations
- NCT07196722 · 1,092 participants · Phase 2
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI